Literature DB >> 25456083

Targeting (cellular) lysosomal acid ceramidase by B13: design, synthesis and evaluation of novel DMG-B13 ester prodrugs.

Aiping Bai1, Zdzislaw M Szulc1, Jacek Bielawski1, Jason S Pierce1, Barbara Rembiesa1, Silva Terzieva1, Cungui Mao2, Ruijuan Xu2, Bill Wu3, Christopher J Clarke2, Benjamin Newcomb2, Xiang Liu4, James Norris4, Yusuf A Hannun5, Alicja Bielawska6.   

Abstract

Acid ceramidase (n class="Gene">ACDase) is being recognized as a therapeutic target for cancer. B13 represents a moderate inhibitor of ACDase. The present study concentrates on the lysosomal targeting of B13 via its N,N-dimethylglycine (DMG) esters (DMG-B13 prodrugs). Novel analogs, the isomeric mono-DMG-B13, LCL522 (3-O-DMG-B13·HCl) and LCL596 (1-O-DMG-B13·HCl) and di-DMG-B13, LCL521 (1,3-O, O-DMG-B13·2HCl) conjugates, were designed and synthesized through N,N-dimethyl glycine (DMG) esterification of the hydroxyl groups of B13. In MCF7 cells, DMG-B13 prodrugs were efficiently metabolized to B13. The early inhibitory effect of DMG-B13 prodrugs on cellular ceramidases was ACDase specific by their lysosomal targeting. The corresponding dramatic decrease of cellular Sph (80-97% Control/1h) by DMG-B13 prodrugs was mainly from the inhibition of the lysosomal ACDase.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Acid ceramidase; B13; Cancer; DMG-B13 prodrugs; Inhibitors; Lysosomes

Mesh:

Substances:

Year:  2014        PMID: 25456083      PMCID: PMC4443482          DOI: 10.1016/j.bmc.2014.10.025

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  45 in total

1.  Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids.

Authors:  Alicja Bielawska; Jacek Bielawski; Zdzislaw M Szulc; Nalini Mayroo; Xiang Liu; AiPing Bai; Saeed Elojeimy; Barbara Rembiesa; Jason Pierce; James S Norris; Yusuf A Hannun
Journal:  Bioorg Med Chem       Date:  2007-08-24       Impact factor: 3.641

2.  Synthesis and bioevaluation of omega-N-amino analogs of B13.

Authors:  Aiping Bai; Zdzislaw M Szulc; Jacek Bielawski; Nalini Mayroo; Xiang Liu; James Norris; Yusuf A Hannun; Alicja Bielawska
Journal:  Bioorg Med Chem       Date:  2009-01-31       Impact factor: 3.641

3.  Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer.

Authors:  M Selzner; A Bielawska; M A Morse; H A Rüdiger; D Sindram; Y A Hannun; P A Clavien
Journal:  Cancer Res       Date:  2001-02-01       Impact factor: 12.701

4.  Structural requirements of ceramide and sphingosine based inhibitors of mitochondrial ceramidase.

Authors:  J Usta; S El Bawab; P Roddy; Z M Szulc; A Hannun; A Bielawska
Journal:  Biochemistry       Date:  2001-08-14       Impact factor: 3.162

5.  Autoproteolytic cleavage and activation of human acid ceramidase.

Authors:  Nataly Shtraizent; Efrat Eliyahu; Jae-Ho Park; Xingxuan He; Ruth Shalgi; Edward H Schuchman
Journal:  J Biol Chem       Date:  2008-02-14       Impact factor: 5.157

6.  Anti-ceramidase LCL385 acutely reduces BCL-2 expression in the hippocampus but is not associated with an increase of learned helplessness in rats.

Authors:  Ziad Nahas; Yan Jiang; Youssef H Zeidan; Alicja Bielawska; Zdzislaw Szulc; Lindsay Devane; Peter Kalivas; Yusuf A Hannun
Journal:  Behav Brain Res       Date:  2008-08-14       Impact factor: 3.332

7.  Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.

Authors:  Johannes Kornhuber; Philipp Tripal; Martin Reichel; Lothar Terfloth; Stefan Bleich; Jens Wiltfang; Erich Gulbins
Journal:  J Med Chem       Date:  2007-11-21       Impact factor: 7.446

8.  Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer.

Authors:  Ayman E M Mahdy; Joseph C Cheng; Jun Li; Saeed Elojeimy; William D Meacham; Lorianne S Turner; Aiping Bai; Christopher R Gault; Alex S McPherson; Nicole Garcia; Thomas H Beckham; Antonio Saad; Alicja Bielawska; Jacek Bielawski; Yusuf A Hannun; Thomas E Keane; Mohhammed I Taha; Hisham M Hammouda; James S Norris; Xiang Liu
Journal:  Mol Ther       Date:  2008-12-23       Impact factor: 11.454

9.  Cationic ceramides and analogues, LCL30 and LCL85, as adjuvants to photodynamic therapy of tumors.

Authors:  Mladen Korbelik; Wei Zhang; Kyi Min Saw; Zdzislaw M Szulc; Alicja Bielawska; Duska Separovic
Journal:  J Photochem Photobiol B       Date:  2013-07-06       Impact factor: 6.252

10.  Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents.

Authors:  Zdzislaw M Szulc; Nalini Mayroo; AiPing Bai; Jacek Bielawski; Xiang Liu; James S Norris; Yusuf A Hannun; Alicja Bielawska
Journal:  Bioorg Med Chem       Date:  2007-08-24       Impact factor: 3.641

View more
  18 in total

1.  Expression of Ceramide Synthase 6 Transcriptionally Activates Acid Ceramidase in a c-Jun N-terminal Kinase (JNK)-dependent Manner.

Authors:  Tejas S Tirodkar; Ping Lu; Aiping Bai; Matthew J Scheffel; Salih Gencer; Elizabeth Garrett-Mayer; Alicja Bielawska; Besim Ogretmen; Christina Voelkel-Johnson
Journal:  J Biol Chem       Date:  2015-04-03       Impact factor: 5.157

Review 2.  Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer.

Authors:  Christina Voelkel-Johnson; James S Norris; Shai White-Gilbertson
Journal:  Adv Cancer Res       Date:  2018-06-20       Impact factor: 6.242

3.  Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis.

Authors:  Shai White-Gilbertson; Ping Lu; James S Norris; Christina Voelkel-Johnson
Journal:  J Lipid Res       Date:  2019-04-15       Impact factor: 5.922

Review 4.  Therapeutic implications of bioactive sphingolipids: A focus on colorectal cancer.

Authors:  E Ramsay Camp; Logan D Patterson; Mark Kester; Christina Voelkel-Johnson
Journal:  Cancer Biol Ther       Date:  2017-07-07       Impact factor: 4.742

5.  The expression profiles and regulation of PD-L1 in tumor-induced myeloid-derived suppressor cells.

Authors:  Chunwan Lu; Priscilla S Redd; Jeffrey R Lee; Natasha Savage; Kebin Liu
Journal:  Oncoimmunology       Date:  2016-10-20       Impact factor: 8.110

6.  Controlling Immunoregulatory Cell Activity for Effective Photodynamic Therapy of Cancer.

Authors:  Mladen Korbelik; Zdzislaw M Szulc; Alicja Bielawska; Duska Separovic
Journal:  Methods Mol Biol       Date:  2022

7.  Targeting Acid Ceramidase Inhibits Glioblastoma Cell Migration through Decreased AKT Signaling.

Authors:  Cyntanna C Hawkins; Amber B Jones; Emily R Gordon; Sarah E Williford; Yuvika Harsh; Julia K Ziebro; Catherine J Landis; Sajina Gc; David K Crossman; Sara J Cooper; Sasanka Ramanadham; Ninh Doan; Anita B Hjelmeland
Journal:  Cells       Date:  2022-06-09       Impact factor: 7.666

Review 8.  The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.

Authors:  Su-Fern Tan; Jennifer M Pearson; David J Feith; Thomas P Loughran
Journal:  Expert Opin Ther Targets       Date:  2017-05-02       Impact factor: 6.902

9.  Dose dependent actions of LCL521 on acid ceramidase and key sphingolipid metabolites.

Authors:  Aiping Bai; Alicja Bielawska; Mehrdad Rahmaniyan; Jacqueline M Kraveka; Jacek Bielawski; Yusuf A Hannun
Journal:  Bioorg Med Chem       Date:  2018-11-10       Impact factor: 3.641

10.  Synthesis of erythro- B13 enantiomers and stereospecific action of full set of B13-isomers in MCF7 breast carcinoma cells: Cellular metabolism and effects on sphingolipids.

Authors:  Aiping Bai; Jacek Bielawski; Alicja Bielawska; Yusuf A Hannun
Journal:  Bioorg Med Chem       Date:  2021-01-08       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.